ORA
Company
ORA develops one asset, in phase 2 (cis-UCA in dry eye syndrome). Mostly small molecule acting on inflammation.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 0
- Signals
Pipeline
1Cis-urocanic acid anti-inflammatory modulator for ocular surface indications.
Phase 2, Small molecule, Inflammation, dry eye syndrome, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials6
- Similar companies6